Pain
Conference Coverage
Neuropathic pain puts cancer survivors out of work
Chronic neuropathic pain is a barrier to employment for many cancer survivors.
Feature
New report highlights gaps in knowledge on marijuana use
Evidence review shows when using cannabis or cannabinoids is effective, ineffective, or harmful.
From the Journals
Screen opioid users for depression, study recommends
Opioid prescribing should be combined with both screening and treatment of depression, a new study shows.
From the Journals
Statin use increases risk of herpes zoster
Statin use, as well as how recent statin exposure occurred, are significant risk factors of herpes zoster.
From the Journals
Giant cell arteritis independently raises risk for venous thromboembolism
The risk of venous thromboembolism increases markedly shortly before the diagnosis of giant cell arteritis regardless of glucocorticoid exposure,...
News from the FDA/CDC
Latest CDC data: Opioid deaths still rising
The U.S. death rate from synthetic opioids, including fentanyl, soared by 72.2% from 2014 to 2015, according to the CDC.
From the Journals
History of complex regional pain syndrome increases risk of secondary CRPS
Secondary complex regional pain syndrome is significantly more likely in people currently experiencing CRPS in an unrelated extremity than in the...
Conference Coverage
Strength of fibromyalgia as marker for seizures questioned
HOUSTON – The specificity of fibromyalgia as a marker for psychogenic nonepileptic seizures is less reliable than previously described, results...
Patient Information
Tips for Living With Myasthenia Gravis
Myasthenia gravis is a chronic autoimmune disease that weakens the body’s muscles and causes fatigue. It results from impaired communication...
Feature
Survey: Primary care needs opioid alternatives
“We were told ... that [opioids] wouldn’t be addictive in the great majority of patients. This was obviously wrong,” said one respondent.
Conference Coverage
VIDEO: PRECISION exonerates celecoxib: cardiovascular risk is no worse than that of nonselective NSAIDs
NEW ORLEANS – The cardiovascular safety profile of the nonsteroidal anti-inflammatory drug (NSAID) celecoxib, a selective inhibitor of COX-2, is...